# ANI Pharmaceuticals offers to acquire Egetis Therapeutics for $560M

ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics for SEK 11.25 per share, totaling approximately SEK 5.6 billion ($560 million). The acquisition is unanimously recommended by Egetis' board.

- Type: Acquisition
- Announced: 2026-11-05
- Value: $560.0M
- Status: announced
- Products: EMCITATE (treatment for peripheral thyrotoxicosis associated with MCT8 deficiency)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [ANI Pharmaceuticals](https://endata.com/companies/95008.md) (acquirer)
- [Egetis Therapeutics](https://endata.com/companies/95009.md) (target)

## Sources

- [investor.anipharmaceuticals.com](https://investor.anipharmaceuticals.com/news-releases/news-release-details/ani-pharmaceuticals-announces-offer-acquire-egetis-therapeutics), 2026-11-05: "This proposed acquisition further accelerates our transformation with a substantial majority of our revenues expected to be derived from higher margin rare disease products by decade’s end."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.